Alendronate

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 14: Line 14:
== Structure ==
== Structure ==
-
[[Image:Alendronate.gif]]<ref>Image from: http://pharmacy-and-drugs.com</ref> Alendronate is a nitrogen-conatining bisphosphonate with
+
[[Image:Alendronate.gif]]<ref>Image from: http://pharmacy-and-drugs.com</ref>
 +
Alendronate is an aminobisphosphonate with a nonhydrolyzable P-C-P.
-
== Target Protein ==
+
== Target Proteins and Bone ==
 +
 
 +
Alendronate not only targets several proteins, but also directly binds to a bone mineral (hydroxyapatite), which causes the inhibition of bone resorption. The mechanism for this has not been elucidated.<ref>http://www.ncbi.nlm.nih.gov/pubmed/20209564</ref>,<ref>http://www.ncbi.nlm.nih.gov/pubmed/16046206</ref>
 +
 
 +
=== Protein-Tyrosine-Phosphatases (PTP) ===
 +
 
 +
Initial reports indicated that alendronate inhibited several types of PTPs, though specific mechanisms are not known. The data does suggest that alendronate works as an antagonist, which means that, when bound, the alendronate does not elicit a response from the protein but rather disallows the binding of an agonist which would cause a change (likely activating) in the protein.<ref>http://www.drugbank.ca/drugs/DB00630</ref>, <ref>http://www.ncbi.nlm.nih.gov/pubmed/8610169</ref>, <ref>http://www.ncbi.nlm.nih.gov/pubmed/9310349</ref>
 +
 
 +
=== Farnesyl Pyrophosphate Synthase (FPPS) ===
<Structure load='2f92' size='450' frame='true' align='right' caption='Shown: The asymmetric subunit of FPPS, not the assumed biological molecule.' scene='Insert optional scene name here' />
<Structure load='2f92' size='450' frame='true' align='right' caption='Shown: The asymmetric subunit of FPPS, not the assumed biological molecule.' scene='Insert optional scene name here' />
 +
 +
FPPS is considered the main target protein of aminobisphosphonates (including alendronate).
<scene name='Sandbox_59/Alen_in_secondary_struct/2'>Bound Alendronate</scene>
<scene name='Sandbox_59/Alen_in_secondary_struct/2'>Bound Alendronate</scene>
Line 34: Line 45:
-
=== Natural Substrates ===
+
==== FPPS Natural Substrates ====
[[Image:IPP.png]]<ref>Image from: http://reference.findtarget.com</ref>
[[Image:IPP.png]]<ref>Image from: http://reference.findtarget.com</ref>

Revision as of 08:15, 11 March 2011

Please do NOT make changes to this Sandbox. Sandboxes 30-60 are reserved for use by Biochemistry 410 & 412 at Messiah College taught by Dr. Hannah Tims during Fall 2012 and Spring 2013.


Contents

Alendronate (Fosamax®)

Alendronate is commonly known for its use in treatment and prevention of osteoporosis in postmenopausal women and men, but is also used to treat Paget's disease (disease that results in deformed and enlarged bones).[1] Alendronate belongs to the class of nitrogen-containing bisphosphonates, which are inorganic pyrophosphate analogues.

History of Bisphosphonates

Bisphosphonates were first synthesized in Germany in 1865, but were not studied biologically until 1968. In the interim time, they were used in the textile and fertilizer industries due to their apparent inhibitory effect on calcium carbonate. However, in 1968, a group in Switzerland found inorganic pyrophosphates in urine and plasma. In vitro testing of these molecules revealed that they inhibited calcium phosphate precipitation and dissolution, but were destroyed in vivo by phosphatases. These results led to the discovery of bisphosphonates, as they reacted in the prescribed manner.[2]

Sodium alendronate was first marketed in 1994 as Fosamax® by Merck pharmaceutical. In 2008, Merck lost their U.S. patent on alendronate, allowing Barr Pharmaceuticals and Teva Pharmaceuticals USA to begin marketing generic forms of sodium alendronate. Other brand names for the drug include Fosamax+D®, Adronat, Alendros, Arendal, and Onclast.[3]

Structure

Image:Alendronate.gif[4] Alendronate is an aminobisphosphonate with a nonhydrolyzable P-C-P.


Target Proteins and Bone

Alendronate not only targets several proteins, but also directly binds to a bone mineral (hydroxyapatite), which causes the inhibition of bone resorption. The mechanism for this has not been elucidated.[5],[6]

Protein-Tyrosine-Phosphatases (PTP)

Initial reports indicated that alendronate inhibited several types of PTPs, though specific mechanisms are not known. The data does suggest that alendronate works as an antagonist, which means that, when bound, the alendronate does not elicit a response from the protein but rather disallows the binding of an agonist which would cause a change (likely activating) in the protein.[7], [8], [9]

Farnesyl Pyrophosphate Synthase (FPPS)

Shown: The asymmetric subunit of FPPS, not the assumed biological molecule.

Drag the structure with the mouse to rotate

FPPS is considered the main target protein of aminobisphosphonates (including alendronate).


FPPS Natural Substrates

Image:IPP.png[10]

Isopentenyl pyrophosphate (IPP) actually binds to and stabilizes the alendronate-FPPS complex, rather than competing with the inhibitor.

Side affects of Drug

References

  1. ↑ http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000018/
  2. ↑ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC138713/?tool=pmcentrez
  3. ↑ http://www.drugbank.ca/drugs/DB00630
  4. ↑ Image from: http://pharmacy-and-drugs.com
  5. ↑ http://www.ncbi.nlm.nih.gov/pubmed/20209564
  6. ↑ http://www.ncbi.nlm.nih.gov/pubmed/16046206
  7. ↑ http://www.drugbank.ca/drugs/DB00630
  8. ↑ http://www.ncbi.nlm.nih.gov/pubmed/8610169
  9. ↑ http://www.ncbi.nlm.nih.gov/pubmed/9310349
  10. ↑ Image from: http://reference.findtarget.com

Proteopedia Page Contributors and Editors (what is this?)

Anne Goodling, David Canner, Justin Myles Kidd, OCA

Retrieved from "http://52.214.119.220/wiki/index.php/Alendronate"
Personal tools